DexCom, Inc

DexCom, Inc. (NASDAQ: DXCM) is a medical device company specializing in continuous glucose monitoring (CGM) systems. It empowers individuals to manage their health in real-time and focuses on advancing diabetes care technology. By addressing the needs of patients, caregivers, and healthcare providers, DexCom strives to simplify and enhance diabetes management globally. The company's primary mission is to design, develop, and commercialize CGM systems to support diabetes management for users, their support networks, and clinicians worldwide.

As per our previous Kalkine’s American Tech Report on ‘DXCM’ on 26^th November 2024, Kalkine provided an ‘Buy’ stance on the stock at USD 77.83 based on technical analysis and the stock price has now moved by ~13.02% since then and has breached resistance 1.

Noted below are the details of support and resistance levels provided in our previous report:

DXCM’s Daily Chart

DexCom faced a non-cash charge in Q4 2024 due to inventory damage during transit and production inefficiencies, impacting its gross margin. Considering the target level attainments and increasing volatility over global equity market a ‘Sell’ rating is assigned to the ‘DXCM’ at the current market price of USD 87.97 as of Jan 27, 2025 (12.50). 

Note: This report may be updated with details around fundamental and technical analysis, price chart in due course, as appropriate.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is Jan 27,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.